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Abstract The aim of the present study was the direct
covalent coupling of the epidermal growth factor receptor
(EGFR)-specific monoclonal antibody (mAb) to the surface
of poly(lactide)-co-glycolide (PLGA)-polyethylene glycol
(PEG) nanoparticles in order to achieve a cell type-specific
drug carrier system against pancreatic cancer. The PLGA-
PEG-NH2 diblock copolymer was synthesized by coupling
reaction via amide linkage between PEG-diamine and activated
PLGA. PLGA and PLGA-PEG-NH2 nanoparticles loaded with
gemcitabine were prepared using the double-emulsion solvent
evaporation method. PLGA-PEG immunonanoparticles were
prepared by glutaraldehyde mediated cross-linking method.
The conjugated antibody was analysed by transmission elec-
tron microscopy and sodium dodecyl sulfate-polyacrylamide
gel electrophoresis (PAGE) analysis. Cell viability study was
performed using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltet-
razolium bromide assay and cell uptake study was performed
on fluorescein isothiocyanate-loaded formulations using con-
focal microscopy. The PAGE results indicated that mAb integ-
rity was remained intact in the formulations after conjugation.
Biological activity was confirmed under cell culture conditions:
antibody-conjugated nanoparticles showed specific targeting to
EGFR-overexpressing MIA PaCa-2 cell lines as shown in
fluorescence image using confocal microscopy. The obtained
data provide the basis for the development of stable and bio-
logically active carrier systems for direct targeting of tumour
cells using antibody-conjugated PLGA-PEG nanoparticles.
Direct covalent coupling of antibodies to nanoparticles using
glutaraldehyde as a cross-linker is an appropriate method
to achieve cell type-specific drug carrier systems based on
PLGA-PEG nanoparticles and the anti-EGFR-decorated
PLGA-PEG nanoparticles have potentials to be applied for
targeted chemotherapy against EGFR positive cancers.
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1 Introduction
Adenocarcinoma of the exocrine pancreas is the fourth leading
cause of cancer deaths in the USA (Berger et al. 2004).
Currently, surgery is the only treatment although, due to its
late presentation, only 9–15 % of the patients are suitable for
surgery. The median survival for all stages of pancreatic
cancer is 3–5 months from diagnosis (Shore et al. 2004).
The underlying problem in the use of anticancer drugs is their
toxicity and poor bioavailability (Langer 1998). It is expected
that if a delivery system-bearing anticancer drugs can be
delivered in a targeted fashion, inhibition of tumour growth
with reduced systemic toxicity will occur. Therefore, new
therapeutic strategies are necessary to combat this deadly
disease. Antibodies are well-established systems to target
drugs or colloidal carriers to specific cell types. This principle
is based on a defined receptor ligand interaction which enables
the surface binding and subsequent cellular internalisation of
drugs or drug carriers conjugated to the antibody. Chemical
modification of the antibody is necessary to enable conjuga-
tion with a drug carrier, but at the same time it is a prerequisite
that while performing conjugation reactions, biological activ-
ity and full receptor binding of the antibody is maintained.
Epidermal growth factor receptor (EGFR) monoclonal anti-
body is directed against the extracellular domain of the recep-
tor. EGFR belongs to a receptor tyrosine-specific protein
kinase family, the EGFR family, which consists of four EGF
receptors, EGFR (ErbB1), ErbB2 (Neu), ErbB3, and ErbB4.
Members of the EGFR family contain a cytoplasmic tyrosine
kinase domain, a single transmembrane domain, and an
extracellular domain that is involved in ligand binding
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and receptor dimerisation (Ferguson et al. 2003; Olayioye et al.
2000). Overexpression of EGFR at the cell surface may lead to
a spontaneous formation of homodimers, but more likely the
availability of the receptor for ligand-driven heterodimerisation
increases (Jorissen et al. 2003). EGFR overexpression trans-
lates into signals that potentiate dysregulated growth, oncogen-
esis, metastasis, and possibly resistance against chemothera-
peutic agents. EGFR is amplified at 50–70 % incidence in
human pancreatic cancer (Dancer et al. 2007). The EGFR
monoclonal antibody (mAb) acts in a cytostatic manner
by blocking and downmodulation of the EGFR receptor
and by antibody-dependent cellular cytotoxicity as major
mechanism of antibody action (Ennis et al. 1991; Xiong and
Abbruzzese 2002). It induces EGFR internalisation and deg-
radation. EGFR mAb offers an excellent strategy for drug
targeting to cancer cells because EGF is an easily accessible
cell surface receptor overexpressed on the primary tumour
as well as on metastatic sites (Bloomston et al. 2006).
The internalisation ability of EGFR allows an efficient uptake
of the antibody alone as well as conjugated to drugs or drug
carrier systems.
Colloidal systems such as nanoparticles provide higher
drug-carrying capacities than antibodies and, therefore, are
especially suited for conjugation to antibodies. Poly(lactide)-
co-glycolide (PLGA)-based nanoparticles represent a colloi-
dal drug carrier systemwith high drug-loading capacity. These
particles are biodegradable, non-antigenic, non-irritative for
tissues, and nontoxic (Mundargi et al. 2008). Drugs can be
incorporated within the particle matrix, adsorbed on the
particle surface or bound by covalent linkage. Especially
incorporation in the particle matrix protects the drug against
degradation and enables controlled release.
The aim of the present study was the direct covalent
coupling of the EGFR mAb to the surface of PLGA-
polyethylene glycol (PEG) nanoparticles in order to achieve
a cell type-specific drug carrier system against pancreatic
cancer.
2 Materials and methods
Gemcitabine hydrochloride was generously gifted by Sun
Pharma (SUPAC, Hyderabad). Poly (D,L -lactic-co-glycolic
acid) 50:50, polyethylene glycol bis amine (PEG diamine),
anti-EGFR mAb were purchased from Sigma Chemical
Laboratories Pvt. Ltd. Mumbai. All other chemicals were
purchased from HiMedia, Bombay and CDH Laboratory
Reagents, New Delhi and were of analytical grade.
2.1 Cell line
The cell line, MIA PaCa-2 cell line (human pancreatic
carcinoma) was obtained from National Centre for Cell
Sciences, Pune, India. Cell line was cultured in
Dulbecco’s modified Eagle’s medium supplemented with
10 % (v /v ) heat-inactivated foetal bovine serum and horse
serum (2.5 %). Cells were maintained in 5 % CO2-humid-
ified incubator at 37 °C. During subculture, cells were
detached by trypsinization when they reached 80 %
confluency and split (1:4). Growth medium was changed
every 3 days.
2.2 Preparation of PLGA-PEG-NH2 diblock copolymer
The PLGA-PEG diblock copolymer was synthesized by
coupling reaction via amide linkage between PEG di-
amine and activated PLGA (Esmaeili et al. 2008), with
minor modifications. The carboxyl terminal end of the
PLGA was first activated with N -hydroxysuccinimide
(NHS) by using dicyclohexylcarbodiimide (DCC).
Briefly, the PLGA (100 mg) was dissolved in DCM
(5 ml); and then DCC (5 mg) and NHS (2.5 mg) were
added under magnetic stirring. The activation reaction of
carboxylic acid end group was accomplished for 12 h at
room temperature. Insoluble dicyclohexyl urea was fil-
tered and the resultant solution was precipitated by
dropping into ice-cold anhydrous diethyl ether. The acti-
vated PLGA was completely dried under vacuum. The
NHS ester of the PLGA was conjugated with PEG di-
amine via amide linkage. The activated PLGA (100 mg)
was dissolved in DCM (5 ml) and excess of PEG di-
amine (35 mg) was added in to this solution. The cou-
pling reactionwas performed under magnetic stirring for 9 h at
room temperature. An excess amount of PEG diamine was
used to prevent the formation of PLGA-PEG-PLGA triblock
copolymers. The amine-terminated PEG-PLGA diblock co-
polymer was precipitated with cold methanol and purified
with excess of ethanol (to eliminate unconjugated PEG di-
amine) and finally dried under vacuum.
2.3 Preparation of nanoparticles
PLGA and PLGA-PEG-NH2 NPs loaded with gemcitabine
were prepared using the double emulsion solvent
evaporation method (Avgoustakis et al. 2002). PLGA
polymer (40 mg) or PLGA-PEG-NH2 copolymer (40 mg)
was dissolved in 4 ml DCM. An aqueous solution of
gemcitabine (V =1 ml, C =5 mg/ml) was emulsified in solu-
tion while vortexing for 20 s and further sonicated using probe
sonicator (ultrasonic liquid processor, Misonix, USA) at an
amplitude of 40W for 1 min to form primary water (w)/oil (o)
emulsion. The emulsion was transferred dropwise to an aque-
ous solution of sodium cholate (V =20 ml, 12 mM) and the
mixture was probe sonicated at an amplitude of 60 W for
3 min to form w/o/w emulsion. The emulsion formed was
gently stirred at room temperature until the evaporation of the
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organic phase was completed. The gemcitabine loaded PLGA
NPs (GEM-PLGA NPs) and GEM-PLGA-PEG-NH2 NPs
were purified by applying two cycles of centrifugation
(22,000 rpm for 20 min) using refrigerated centrifuge
(Laborzentrifugen, Sigma 3K30) and reconstituted with de-
ionized and distilled water. Blank NPs were also prepared by
the same method without adding gemcitabine at any stage of
the preparation.
2.4 Characterization of nanoparticles
Characterization of NPs was done on the basis of size, zeta
potential and entrapment efficiency. The method used for
preparation of NPs was optimized on the basis of change in
amount of polymer, concentration of drug and surfactant
(Govender et al. 1999; Acharya et al. 2009).
2.4.1 Optimization of process parameters
Optimization of concentration of drug NPs were optimized
for different concentration of gemcitabine (5, 7, and 10mg/ml)
with respect to particle size and entrapment efficiency.
Optimization of amount of polymer NPs were prepared
varying the amount of polymer using 20, 40, and 60 mg
of PLGA while keeping the concentration of drug and
surfactant constant. The formulations were optimized on
the basis of size and entrapment efficiency.
Optimization of concentration of surfactant Different for-
mulations were prepared using different concentrations of
surfactants (8, 10, and 12 mM) while keeping concentration
of drug and polymer constant. The formulations were eval-
uated for particle size and entrapment efficiency.
2.4.2 Size and zeta potential
The average particle size and zeta potential of optimized
formulations were determined by photon correlation spectros-
copy using Zetasizer (Beckman Coulter, UK). The samples
were kept into the cuvettes of zetasizer and the size, polydis-
persity index (PDI), and zeta potential were measured.
2.4.3 Entrapment efficiency
The method adopted for estimating the entrapment efficiency
was a slight modification to the extraction method followed
(Blanco and Alonso 1997). The amount of gemcitabine
entrapped in NPs was estimated by adding 5 mg of NPs in
1 ml of acetonitrile and shaking NPs vigorously in order to
solubilise the polymer so as to extract out the drug followed by
addition of 4 ml of PBS 7.4 to solubilise the drug. The amount
of gemcitabine was measured by UV spectrophotometer
(Shimadzu, Japan) using a detection wavelength of 270 nm.
The percentage drug entrapment was measured as:
% DEE ¼ amount of drug entrapped
amount of drug added
 100
2.4.4 Scanning electron microscopy
Scanning electron microscopy (SEM) was used to examine
the shape and morphology of the NPs (Govender et al. 1999;
Acharya et al. 2009). The NPs were placed on sample holder,
coated with gold-palladium alloy (150–250 Å) using a sputter
coater and then placed in scanning electron microscope.
2.4.5 In vitro drug release
The in vitro drug release profile of entrapped drug from NPs
was studied using dialysis membrane. Each dialysis bag
(pore size, 12 kDa; Sigma Chemical Co., USA) was loaded
with lyophilized preparation equivalent to 2.5 mg of drug. The
dialysis bag was then placed in 50 ml PBS (pH 7.4), contain-
ing 1 % tween 80, at 37±1 °C and under 100 rpm stirring.
Samples (5 ml) were withdrawn at predetermined time inter-
val and replaced with the same volume of fresh dialyzing
medium and the withdrawn samples were assayed for drug
content by measuring absorbance at 270 nm against the blank
using UV spectrophotometer (Li et al. 2001).
2.5 Preparation of PLGA-PEG immunonanoparticles
The PLGA-PEG immunonanoparticles (Ab-PLGA NPs)
were prepared by two methods.
1. Glutaraldehyde mediated cross-linking.
The Ab-PLGA NPs were prepared with slight mod-
ifications in reported method (Hun and Zhang 2009).
PLGA-PEG-NH2 NPs were prepared using optimized
formulation of PLGA NPs. NPs (4 mg) were dispersed
in PBS 7.4 containing glutaraldehyde (25 %) up to a
final concentration of 1.25 %, for about 2 h. The excess
of glutaraldehyde was separated from NPs using dialy-
sis membrane (12 kDa). The presence of free aldehydic
group of glutaraldehyde was detected by addition of
Schiff reagent (25 μL of Schiff reagent was added to
250 μL of NPs formulation). Glutaraldehyde-activated
NPs were further incubated with anti-EGFR antibody
(1 mg/ml) for 12 h at 4 °C with continuous shaking.
The anti-EGFR antibody conjugated NPs (glutaralde-
hyde Ab-PLGA NPs) were centrifuged at 22,000 rpm
at 4 °C for 20 min to remove excess antibody and kept
at 4°C in PBS 7.4.
2. MBS cross-linking
The antibody conjugation was also performed by
thiolation of mAb with slight modifications in reported
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method (Steinhauser et al. 2006). The PLGA-PEG-NH2
NPs were dispersed in 1 ml PBS (pH 7.2) and the cross-
linker m -maleimidobenzoyl-N -hydroxysuccinimide
(MBS; 3.14 mg) was dissolved in 1 ml of dimethyl
sulfoxide (DMSO). MBS solution (100 μl) was
added in 1 ml NPs dispersion and incubated for 30 min
at 25 °C in shaker incubator. The excess of MBS was
separated from activated NPs using sephadex G25. For
thiolation of anti-EGFR antibody, 5.7 mg of 2-
iminothiolane (Traut’s reagent) was dissolved in 5 ml
PBS (pH 7.4) and 100 μl anti-HER-2 mAb was incubated
with 4.2 μl of 2-iminothiolane for 2 h at 20 °C
under constant shaking. Finally, 100 μl thiolated mAb
was added in 100 μl MBS-activated NPs for 30 min at
25 °C under constant shaking for preparation of PLGA-
PEG immunonanoparticles.
2.6 Characterization of Ab-PLGA NPs
2.6.1 Transmission electron microscopy
Transmission electron microscopy (TEM) was done for
both the prepared Ab-PLGA NP conjugates (Acharya
et al. 2009). Dispersions were visualized under TEM with
an accelerating voltage of 100 kV. A drop of the sample
was placed on to a carbon-coated copper grid to leave a
thin film on the grid. The film was negatively stained with
1 % phosphotungastic acid solution and dried. A drop of
the staining solution was added on to the film and the
excess of the solution was drained off. The grid was
allowed to dry at ambient temperature and samples were
viewed under transmission electron microscope (Hitachi,
Japan) and photographs were taken at suitable magnification.
2.6.2 Size and zeta potential
The size, PDI, and zeta potential of optimized formula-
tions were determined by photon correlation spectroscopy
method using zetasizer (Beckman Coulter). The samples
were loaded into the cuvettes of zetasizer and the size,
PDI, and zeta potential were measured (Acharya et al.
2009).
2.6.3 Entrapment efficiency
The amount of gemcitabine entrapped in NPs was esti-
mated by adding 5 mg of NPs in 1 ml of acetonitrile and
shaking NPs vigorously in order to solubilise the polymer
so as to extract out the drug followed by addition of 4 ml
of PBS 7.4 to solubilise the drug. The amount of
gemcitabine was measured by UV spectrophotometer
using a detection wavelength of 270 nm (Blanco and
Alonso 1997).
2.6.4 Sodium dodecyl sulfate-polyacrylamide gel
electrophoresis
Sodium dodecyl sulphate (SDS) gel electrophoresis is
widely used for the analysis and characterization of protein
samples. It is useful in molecular weight determination,
relative estimation of purity, and amino acid sequencing
of proteins. In the present study, conjugation efficiencies
were evaluated by SDS-polyacrylamide gel electrophoresis
(PAGE), allowing comparison of free mAb fragment vs.
conjugated NPs (Flatman et al. 2007). SDS-PAGE was done
for both the prepared conjugated NPs.
2.6.5 Optimized Ab-PLGA NPs
The method for the preparation of immunonanoparticles
was optimized on the basis of morphology (TEM), size,
zeta potential, and entrapment efficiency. The optimized
formulation was used for cell line studies.
2.7 In vitro evaluation
In vitro evaluation of prepared formulations was carried out
on cell lines using MIA PaCa-2 cell line (human pancreatic
carcinoma). The studies included cell viability assay (using
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) dye) and cellular uptake studies (using confocal
microscopy).
2.7.1 Cell viability assay
Cell viability was tested using MTT assay (Wang et al.
1996; Acharya et al. 2009) based on the cleavage of
yellow tetrazolium salt MTT by metabolically active cells
to form an orange formazan dye which was quantified
using ELISA reader (Biorad, USA, model 680). Cells
were seeded in 96-well microtitre plates (2×104 cells/
200 μL growth medium/well) followed by overnight
incubation. Supernatants from the wells were aspirated
out and fresh aliquots of growth medium (containing
NPs, i.e., GEM-PLGA NPs, blank PLGA NPs, GEM-
Ab-PLGA NPs, and blank Ab-PLGA NPs) in desired
concentrations in the range of 2–32 μg/mL were added.
Blank formulations were used as control. After 24 h,
supernatants were aspirated out and the cell monolayers
in the wells were washed with 200 μL PBS (0.1 M, pH 7.4).
Subsequently, MTT reagent (150 μL, 0.8 mg/mL) was
added in each well, incubated for 5 h. DMSO (100 μL) was
added in each well after aspirating out the supernatant
and incubated at 37 °C for 1 h. Absorbance at two
wavelengths (570 nm for soluble dye and 630 nm for
cells) were recorded using ELISA reader. Concentrations
of samples showing 50 % reduction in cell viability (i.e.,
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IC50 values) were then calculated. An optical density value of
control cells (unexposed cells) was taken as 100 % viability
(0 % cytotoxicity).
2.7.2 Cell uptake studies
Preparation of fluorescence marker loaded nanoparticles The
NPs encapsulating fluorescence marker (fluorescein iso-
thiocyanate, FITC) was prepared by the double emulsi-
fication solvent evaporation technique as described ear-
lier. Polymer or copolymer (40 mg) was dissolved in 4 ml
dichloromethane. An aqueous solution of FITC (V =1 ml,
C =1 mg/ml) was emulsified in solution while vortexing for
20 s and further sonicated using probe sonication (ultrasonic
liquid processor, Misonix, USA) at 10 W for 1 min to
form primary w/o emulsion. The emulsion was trans-
ferred dropwise to an aqueous solution of sodium cho-
late (V =20 ml, 12 mM) and the mixture was probe
sonicated at 18 W for 3 min to form w/o/w emulsion.
The emulsion formed was gently stirred at room tem-
perature until the evaporation of the organic phase was
complete. The NPs were purified by applying two cy-
cles of centrifugation (22,000 rpm for 20 min) using
refrigerated centrifuge (Laborzentrifugen, Sigma 3 K30)
and reconstituted with deionized-distilled water. The
prepared NPs were further conjugated to anti-EGFR
antibody using glutaraldehyde-mediated cross-linking
described previously.
Procedure for cell uptake studies EGFR positive MIA
PaCa-2 cells were seeded on glass cover slips (18×
18 mm) placed into 35 mm tissue culture plates at a density
of 2×105 cells (in 2 mL growth medium). After overnight
growth, supernatants from the culture plates were aspirated
out and fresh aliquots of growth medium containing suspen-
sion of FITC-loaded PLGA NPs and FITC-loaded Ab-PLGA
NPs were added at the concentration of 0.25 mg/ml and
incubated at 37 °C for 6 h. Upon incubation for 6 h, cells
were washed with PBS, fixed in 4 % formaldehyde for
20 min, and then washed twice with PBS and observed under
confocal laser scanning microscope (CLSM) (Fluoview 1000,
Olympus, USA) after excitation at 490 nm (Acharya et al.
2009).
2.8 Statistical analysis
All experiments were carried out three times, independent-
ly. The data obtained were expressed in terms of “mean±
standard deviation” values. Wherever appropriate, the data
were also subjected to unpaired two-tailed Student’s t test.
A value of p <0.05 was considered as significant. Asterisk
(*) in figure denotes a statistically significant difference
compared to control (p <0.05).
3 Results
3.1 Optimization parameters of PLGA NPs
3.1.1 Optimization of concentration of drug
Different concentrations of gemcitabine (5, 7.5, and 10mg/ml)
were used for preparation of NPs while amount of polymer
and concentration of surfactant were kept constant. The
concentration of drug was optimized on the basis of size
and entrapment efficiency (Table 1). Formulation D2 (drug,
7.5 mg/ml) was found to be optimum for tumour delivery as
this formulation showed the smallest size of 178±8 nm.
The size of the other two formulations was recorded to be
higher. Also, formulation D2 showed maximum entrapment
efficiency (35.17±1.0 %) amongst all the three formulations.
3.1.2 Optimization of amount of polymer
The amount of polymer was optimized keeping drug con-
centration at its optimum level and surfactant concentration
constant in order to obtain formulation of desirable size and
entrapment efficiency. NPs were prepared using different
amounts of polymer (20, 40, and 60 mg). Formulation P2
was found to be optimum on the basis of the lowest particle
size of 178±8.5 nm and highest entrapment efficiency of
34.9±0.89 % (Table 2).
3.1.3 Optimization of concentration of surfactant
Concentration of sodium cholate was optimized using opti-
mized amount of polymer and drug. NPs were prepared using
different concentrations of surfactant (8, 12, and 16 mM). The
NPs prepared using 12 mM (formulation S2) were found to be
optimum on the basis of lowest particle size of 178±10 nm
and highest entrapment efficiency of 33.6±1.2 % (Table 3).
3.2 Morphological study (SEM)
The morphological appearance of the developed NPs was
examined by SEM. The SEM images are shown in Fig. 1a,b
which indicates that PLGA NPs and PLGA-PEG NPs were
almost spherical in nature and free from debris. Table 4 shows
Table 1 Optimization of amount of drug (n =3)
Code Amount (mg) Size (nm) Entrapment efficiency (%)
D1 5 254.9±6.5 24.5±1.3
D2 7.5 178±8 35.17±1.0
D3 10 216±5.5 19.8±0.8
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the various parameters for optimized formulations of PLGA
NPs and PLGA-PEG NPs.
3.3 In vitro release studies
The in vitro release profile of entrapped drug from NPs was
determined in PBS (pH 7.4) using dialysis bag. The release
study of both PLGA and PLGA-PEG-NH2NPswas performed
three times to check the reproducibility. The release behaviours
of both the formulations were comparatively different from
each other. The release behaviour involved two different mech-
anisms, one was the diffusion of drug and the other was the
degradation of polymer matrix. The burst release of drug was
due to the drug which had been adsorbed at the surface of
polymer, which diffused out easily during initial incubation
time (Asadishad et al. 2010). It was observed that 6.93±1.00%
of drug was released within initial 0.5 h and 36.9±1.10 %
was released in 48 h from PLGA NPs. In contrast to PLGA
NPs, PLGA-PEG-NH2 NPs showed release of 9.3±1.54 and
47±1.80 % in 0.5 and 48 h, respectively. Figure 2 shows the
release profile of both GEM-PLGA and GEM-PLGA-PEG-
NH2 NPs.
3.4 Characterization of Ab-PLGA NPs
3.4.1 Morphological study (TEM)
The conjugation of antibody to the surface of nanoparticle
was confirmed by TEM. TEM was performed for PLGA
NPs as well as Ab-PLGA NPs prepared by MBS-mediated
cross-linking and glutaraldehyde cross-linking. The images
revealed that conjugation was successfully done in both the
conjugates but the conjugation with glutaraldehyde was
more efficient than MBS crosslinked Ab-PLGA NPs, as
more antibodies were conjugated to the PLGA-PEG NPs
following glutaraldehyde conjugation. Figures 3 and 4a,b
shows the TEM images of PLGA nanoparticle, glutaralde-
hyde, and MBS cross-linked Ab-PLGA NPs, respectively.
3.4.2 Size and zeta potential
The size of prepared Ab-PLGA NPs should be in the suitable
range for intravenous administration, after conjugation of the
antibody on the NPs. Particle charge determines the stability
of NPs. The particle size, size distribution, and zeta potential
of the glutaraldehyde mediated Ab-PLGA NPs are shown in
Fig. 5a,b, respectively. Figure 6a,b shows the size, size distri-
bution, and zeta potential of MBS cross-linked Ab-PLGANPs.
3.4.3 Entrapment efficiency
The entrapment efficiency of gemcitabine-loaded Ab-
PLGA NPs was estimated and repeated three times. The
formulation showed good reproducible results. Table 5





S1 8 243±7.5 22±1
S2 12 178±10 33.6±1.2
S3 16 204±9.5 30.6±1.4
Fig. 1 a SEM photograph of PLGA NPs. b SEM photograph of
PLGA-PEG NPs
Table 2 Optimization of amount of polymer (n=3)
Code Amount (mg) Size (nm) Entrapment efficiency (%)
P1 20 206.6±9.5 20.5±1.4
P2 40 178±8.5 34.9±0.89
P3 60 392±7 34±0.94
Table 4 Various parameters of optimized formulation of PLGA and
PLGA-PEG-NH2 NPs




1 Size (nm) 178±8.5 132.5±10
2 Polydispersity index (PDI) 0.095±0.04 0.072±0.03
3 Zeta potential (mV) −59.88±3.5 −38.43±2.3
4 % Drug entrapment
efficiency
35.16±1.04 34.56±1.35
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shows the entrapment efficiency of Ab-PLGA NPs along
with other characterization parameters.
3.4.4 SDS-PAGE
The integrity of anti-EGFR antibody after conjugation on the
NPs surface was analyzed by SDS-PAGE in comparison with
the native anti-EGFR antibody (mAb). SDS-PAGE was run
for both the conjugated NPs that is MBS crosslinked Ab-
PLGA NPs and glutaraldehyde crosslinked Ab-PLGA NPs.
Figure 7 shows SDS-PAGE of glutaraldehyde cross-linked
and MBS cross-linked Ab-PLGA NPs. Lane 1 shows the
SDS-PAGE for MBS crosslinked NPs, lane 2 represents
PAGE for glutaraldehyde crosslinked NPs, and lane 3 shows
PAGE run of standard anti-EGFR mAb. The PAGE results
indicate that mAb integrity remained intact in both the sam-
ples after conjugation.
Fig. 2 In vitro release of PLGA
and PLGA-PEG-NH2
nanoparticles
Fig. 3 TEM image of PLGA NPs
Fig. 4 a TEM image of Glu-Ab-PLGA NPs. b TEM image of MBS-
Ab-PLGA NPs
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Fig. 5 a The size and size distribution. b Zeta potential of Glu-GEM-Ab-PLGA NPs
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Fig. 6 a The size and size distribution. b Zeta potential of MBS cross-linked Ab-PLGA NPs
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3.4.5 Optimization of conjugation method
On the basis of morphology, size, and zeta potential, the
conjugation method of antibody to the NPs was selected and
used for further experimentation. Out of both the prepared Ab-
PLGA NPs, glutaraldehyde cross-linked immunonanoparticle
were found to be optimum and used further for cell line studies.
3.5 In vitro evaluation
3.5.1 Cell viability assay
The cell viability assay was performed on MIA PaCa-2 cell
lines. IC50 values were found to be 16 and 31 μg/ml for drug-
loaded PLGA NPs and drug-loaded Ab-PLGA NPs, respec-
tively. Plain drug showed an IC50 of 15 μg/ml (Fig. 8).
3.5.2 Cell uptake studies
NPs encapsulated with fluorescent dye were used to study
cellular uptake. FITC, fluorescent dye was incorporated in
NPs as a marker for fluorescence microscopy to study the
NPs uptake in cells. The fluorescence image shows the uptake
of NPs in the cells. CLSM images of the MIA PaCa-2 cells
after incubation of FITC loaded NPs and Ab-PLGA NPs
suspension for 6 h at 37 °C are shown in Fig. 9.
4 Discussion
The prime objective of the study was to prepare and eval-
uate Ab-PLGA NPs derived from PLGA-PEG diblock co-
polymer. Both the polymer and copolymer were biocom-
patible and biodegradable biomaterial. The PLGA-PEG
diblock copolymer was synthesized by coupling reaction
between primary amine group of PEG diamine and terminal
carboxylic end group of PLGAvia amide linkage. The w/o/w
double emulsification solvent evaporation method was used
for encapsulating hydrophilic drug, gemcitabine. The method
is reported to be the most suitable for encapsulating water-
soluble drugs in polymeric carriers. An important step in the
preparation of NPs was the formation of a stable homogenous
primary emulsion, as the droplet size of dispersed phase in
primary emulsion is directly related to the final NPs size. By
applying sonication, which induced ultrasonic waves, emul-
sion droplets smaller than 0.5 μm were obtained leading to
NPs of the nanosize. Several process parameters were varied
to identify their influence on the particle size and entrapment
Table 5 Characteriza-
tion parameters of Ab-
PLGA NPs




Glutaraldehyde-mediated Ab-PLGA NPs 146.5 0.167 −32.65 31.43±1.58
MBS mediated-Ab-PLGA NPs 446.5 0.216 −10.13 29.58±2.14
Fig. 7 SDS-PAGE of antibody-conjugated PLGA nanoparticles. 1
The SDS-PAGE for MBS cross-linked NPs, 2 PAGE for glutaralde-
hyde cross-linked NPs, and 3 PAGE run of standard anti-EGFR mAb
Fig. 8 Percent viability measured by MTT assay on human pancreatic
cells. An optical density value of unexposed cells, PLGA NPs, and Ab
PLGA-PEG NPs was taken as 100 % viability (0 % cytotoxicity) for
drug, drug-loaded PLGA, and drug-loaded Ab PLGA-PEG NPs, respec-
tively. *p <0.05, compared to plain drug
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efficiency keeping the other parameters constant (primary
sonication amplitude (40 W) for 2 min and secondary sonica-
tion amplitude (60 W) for 4 min; volume of DCM (4 ml) and
volume of sodium desoxycholate solution (20 ml)). The
amount of drug, amount of polymer, and concentration of
surfactant used in formulation were optimized.
The concentration of drug that is added in the formulation
during emulsification process also affects the morphology and
physicochemical properties of the resultant NPs. The drug that
is added in the primary emulsion shows the tendency to
rapidly partition out into the outer aqueous phase (being
hydrophilic in nature), thus higher drug amount would result
in low entrapment efficiency. The amounts of drug used for
optimization were 5, 7.5, and 10 mg. Out of the three formu-
lations prepared, i.e., D1, D2, and D3; formulation D2 was
found to be most suitable on the basis of size as well as
entrapment efficiency. The amount of polymer used for the
preparation of NPs also caused variation in size and entrap-
ment. Increasing the amount of polymer, beyond an optimum
range would result in increase in size of the formulation and an
additional amount of energy would be required to reduce the
size to desired range. Thus the amount of polymer used for
formulating NPs was also optimized and three formulations
P1, P2, and P3 were prepared using 20, 40, and 60 mg of
polymer. Of the prepared formulations, P2 responded well to
the chosen parameters. The size of the formulation prepared
using 40 mg of polymer was lesser and entrapment efficiency
was higher of all the three formulations. Increasing the amount
of polymer, i.e., 60 mg resulted in increase in size beyond
acceptable range. Furthermore, the concentration of surfactant
would result in variation in selected parameters. Surfactant
in less concentration would not be able to stabilize the NPs
whereas, in high concentration, it results in aggregation of
NPs. Thus, for optimizing concentration of surfactant, again
three formulations S1, S2, and S3 were prepared using 8, 12,
and 16 mM of sodium desoxycholate. Of the three formula-
tions, S2 was optimized on the basis of desired size and
maximum entrapment of all the three formulations.
The optimized method was utilized to formulate the NPs
using both PLGA and PLGA-PEG diblock copolymer for
drug delivery. The use of PLGA-PEG diblock copolymer
enables the preparation of non-aggregating particles with-
out the need of an additional stabilizer such as poly (vinyl
alcohol). Furthermore, PEG is an uncharged, highly flexible
polymer that is known to decrease drug adsorption and cell
interactions when present at the surface. PEG has outstanding
physiochemical and biological properties including solubility
in water and in organic solvents. Furthermore, it is non-toxic,
non-antigenic, and non-immunogenic. Morphological studies
were performed utilizing SEM. The particles were observed to
be spherical, smooth and morphologically similar. The size of
the optimized formulations was also found to be in nanorange,
i.e., 178±8.5 and 132.5±10 nm for PLGA and PLGA-PEG
NPs, respectively.
The drug entrapment in case of optimized formulations was
also found to bemore than other formulations and was 35.16±
1.04 % for PLGA and 34.56±1.35 % for PLGA-PEG-NH2
NPs. The polydispersity index was also found to be very less,
i.e., 0.095 and 0.072 for PLGA and PLGA-PEG-NH2 NPs,
respectively, depicting a uniform size distribution for both the
formulations. PLGA NPs exhibited highest zeta potential
(−59.88±3.5 mV) due to the presence of free carboxyl end
group on particle surface whereas in case of PLGA-PEG-NH2
NPs the zeta potential (−38.43±2.3 mV) was found to get
Fig. 9 Confocal laser scanning
micrographs of MIA PaCa-2
pancreatic cancer cells after 6 h
incubation with the FITC-loaded
(a) PLGA NPs (b ) Ab-PLGA
NPs at 0.25 mg/ml nanoparticle
concentration at 37 °C
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shifted to lesser negative value due to the presence of amine
terminated PEG chains because the coating layer shields and
move the shear plane outwards from the particle surface. A
marked difference in the surface charge between PLGA and
PLGA-PEG-NH2 NPs was observed. The result confirms that
the amine terminated PEG chains were situated on the surface
of the NPs. The hydrophilic NH2-PEG moiety was oriented
outside towards aqueous medium forming corona type, which
was anchored to hydrophobic PLGA polymer backbone as a
core material.
The in vitro release profile of PLGA and PLGA-PEG-NH2
NPs was determined in PBS (pH 7.4) at 37 °C using a constant
shaking incubator. The drug release profile was studied for
various time intervals, i.e., 0.5, 1, 2, 4, 6, 8, 16, 24, 36, and
48 h. Both formulations exhibited a biphasic release pattern
that was characterized by an initial burst up to 10 h, followed
by a slower sustained release and remained constant up to
48 h. At the end of 48 h, the PLGA-PEG-NH2 NPs showed
higher release rate of drug than PLGA NPs. The PLGA-PEG-
NH2 NPs degraded quickly and released the drug subsequent-
ly. This could be explained by the degradation mechanisms;
the PEG chains (being hydrophilic) enhanced the water pen-
etration into the matrix and the NPs were degraded homoge-
neously over time. In contrast, PLGA formulation released
only 36.9±1.1 % drug due to its hydrophobicity and hence
poor degradation in aqueous environment. It is inferred that
the gradual degradation of the polymer resulted in sustained
release of the drug. However, the release of gemcitabine
depends on several factors including the drug to polymer ratio,
drug solubility inside the matrix, and the interaction between
the core and drug.
The aim of this studywas to prepareAb-PLGANPs derived
from PLGA-PEG-NH2 block copolymers containing function-
al groups at the PEG chain end allowing NPs surface modifi-
cation for targeting purposes. Amine groups were chosen to
couple targeting units by using two different conjugation tech-
niques, one involving glutaraldehyde as a cross-linker and
other method involved MBS modification of NPs. The former
involved applying aldehyde chemistry in aqueous media. NPs
were prepared from PLGA-PEG-NH2 copolymers and the
coupling of anti-EGFR mAb (as an antibody for pancreatic
cell for targeting units) to glutaraldehyde-activated NPs at the
surface was studied. The excess of glutaraldehyde was re-
moved after the activation of NPs using dialysis membrane.
The free aldehyde group present on the activated NPs was
made to react with amine moiety of antibody. The removal of
excess of glutaraldehyde was confirmed using Schiff reaction.
At different time intervals, 250 μl of glutaraldehyde mixed
formulation was taken and 25 μl of Schiff reagent was added,
which turns deep purple if glutaraldehyde is present. The
decrease in intensity of colour showed almost removal of
excess glutaraldehyde. The second technique for conjugation
involved activation of NH2 moiety of NPs using MBS and
thiolation of mAb using Traut’s reagent, respectively. Later,
both the active moieties were incubated for 30 min to allow
conjugation of both the units.
Both the conjugated Ab-PLGA NPs were characterized on
the basis of size, PDI, zeta potential, and entrapment efficien-
cy. The size of MBS cross-linked NPs was much higher and
was beyond acceptable range. Also, zeta potential depicted
comparatively lower stability of MBS-conjugated NPs. The
entrapment efficiency of former was also lower which might
be due to dissolution of NPs because of use of DMSO as
cosolvent during activation of PLGA-PEG-NH2. TEM images
also revealed that favourably more antibody was coupled
using glutaraldehyde as a cross-linker as compared to MBS-
mediated conjugation.
The particle size of Ab-PLGA NPs was slightly in-
creased than plain PLGA-PEG NPs. Moreover, polydisper-
sity index of the Ab-PLGA NPs was higher. The reason
could be that, during immobilization, a small fraction of the
glutaraldehyde-activated NPs might have reacted with other
NPs, leading to bridging between two particles. The anti-
EGFR antibody attachment showed comparatively little
effect on drug entrapment efficiency.
Anti-EGFR antibody might become inactive due to irre-
versible denaturation and aggregation during the immuno-
nanoparticle preparation process. The integrity of anti-
EGFR antibody after conjugation on the NPs surface was
analyzed by SDS-PAGE in comparison with the native anti-
EGFR antibody. The SDS-PAGE showed that the molecular
weight of both the antibody conjugated NPs was shifted
towards the higher side as compared to native anti-EGFR
antibody. From the comparison of the native antibody and
antibody conjugated on surface of PLGA-PEG NPs, it can
be concluded that antibody conjugated on both the NPs
surface was almost same in structure as the native EGFR
antibody, which also validates the feasibility of Ab-PLGA
NPs for EGFR overexpressed cancer targeting. On the basis
of results obtained, the glutaraldehyde-mediated conjuga-
tion was selected for further in vitro cell line studies.
In cytotoxicity study, gemcitabine concentrations in all the
formulations were adjusted to be the same. Percentage cell
viability of both the formulations at different concentrations in
MIA PaCa-2 cell line was determined. Ab-PLGANPs showed
significantly higher cytotoxic effect (IC50 16 μg/ml) than
PLGA NPs (IC50, 31 μg/ml) after 24-h incubation period in
MIA PaCa-2 cell line, which might be due to lower cellular
uptake of PLGA NPs as compared to Ab-PLGA NPs. The
anti-EGFR monoclonal antibody attached on the surface of
NPs for targeting EGFR positive MIA PaCa-2 pancreatic
cancer cells produced a synergistic effect with anticancer drug
depicting possible role of antibody in blocking cellular signal-
ing, thus leading to inhibition of cellular proliferation. In vitro
cytotoxicity results of Ab-PLGA NPs (without drug) also
support this finding. The blank PLGA-PEGNPs also exhibited
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low cytotoxicity in MIA PaCa-2 cell lines. It implies that these
NPs could be useful as drug carriers without any significant
cytotoxic effects. The significant cytotoxicity was shown by
antibody alone and synergistic effect was shown along with
gemcitabine.
NPs encapsulated with fluorescent dyes are frequently
used to study cellular uptake. FITC, fluorescent dye, was
incorporated in NPs as a marker for fluorescence micros-
copy to study the NPs uptake in cells. Aggregates of the
green colour of FITC-loaded NPs in cell cytoplasm indicate
that NPs were internalised by the cells. It can thus be
concluded that the fluorescent NPs were located inside the
cells. In the present study, the cellular uptake of Ab-PLGA
NPs was higher than that of PLGA NPs as shown by high
intensity fluorescence developed by antibody-conjugated
NPs as compared to PLGA NPs, in EGFR-positive MIA
PaCA-2 cells. The results reveal that anti-EGFR antibody-
conjugated NPs were successfully developed for specifical-
ly targeting EGFR receptors in pancreatic cancer cells.
5 Conclusion
The study provide the basis for the development of stable
and biologically active carrier systems for direct targeting
of tumour cells using antibody-conjugated PLGA-PEG
NPs. Direct covalent coupling of antibodies to NPs using
glutaraldehyde as a cross-linker is an appropriate method
to achieve cell type-specific drug carrier systems based
on PLGA-PEG NPs and the anti-EGFR decorated PLGA-
PEG NPs have potentials to be applied for targeted chemo-
therapy against EGFR-positive cancer. Such a nanoparticle
system for drug delivery is multifunctional, which provides a
platform to formulate anticancer drugs which reduces the side
effects of the formulated anticancer drug, promotes synergistic
therapeutic effects, and achieves targeted delivery for the
therapy.
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